[HTML][HTML] Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary …
S Ikeda, A Sekine, T Baba, T Katano, E Tabata… - BMC pulmonary …, 2019 - Springer
Background Current clinical practice guidelines for idiopathic pulmonary fibrosis (IPF)
conditionally recommend use of pirfenidone and nintedanib. However, an optimal treatment …
conditionally recommend use of pirfenidone and nintedanib. However, an optimal treatment …
[HTML][HTML] Real-world study analysing progression and survival of patients with idiopathic pulmonary fibrosis with preserved lung function on antifibrotic treatment
S Noor, S Nawaz, N Chaudhuri - Advances in therapy, 2021 - Springer
Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible
lung disease. Licensed treatment options for IPF are pirfenidone and nintedanib. The aim of …
lung disease. Licensed treatment options for IPF are pirfenidone and nintedanib. The aim of …
Management of idiopathic pulmonary fibrosis
R Pleasants, RM Tighe - Annals of Pharmacotherapy, 2019 - journals.sagepub.com
Objective: Provide information for pharmacists on idiopathic pulmonary fibrosis (IPF) and its
treatment. Study Selection and Data Extraction: All articles with data from randomized …
treatment. Study Selection and Data Extraction: All articles with data from randomized …
[HTML][HTML] Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
Background Patients with idiopathic pulmonary fibrosis (IPF) demonstrate a range of lung
function impairment. However, the efficacy of antifibrotics compared with placebo has not …
function impairment. However, the efficacy of antifibrotics compared with placebo has not …
[HTML][HTML] Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
S Jouneau, B Crestani, R Thibault, M Lederlin… - Respiratory …, 2020 - Springer
Background Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …
The clinical impact of major comorbidities on idiopathic pulmonary fibrosis
A Suzuki, Y Kondoh - Respiratory Investigation, 2017 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating disease with a median
survival time of 2–3 years after diagnosis. Patients with IPF exhibit distinct patterns of …
survival time of 2–3 years after diagnosis. Patients with IPF exhibit distinct patterns of …
Novel management strategies for idiopathic pulmonary fibrosis
K Ahmad, SD Nathan - Expert Review of Respiratory Medicine, 2018 - Taylor & Francis
Introduction: Idiopathic pulmonary fibrosis (IPF) treatment was revolutionized by the advent
of two novel antifibrotics, nintedanib and pirfenidone. However, neither is a panacea and …
of two novel antifibrotics, nintedanib and pirfenidone. However, neither is a panacea and …
[HTML][HTML] Current approaches to the management of idiopathic pulmonary fibrosis
G Raghu, L Richeldi - Respiratory medicine, 2017 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease
associated with dyspnoea, cough and impaired quality of life. Currently, the aims of patient …
associated with dyspnoea, cough and impaired quality of life. Currently, the aims of patient …
[HTML][HTML] Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study
Background Patients with fibrotic interstitial lung disease (ILD) are frequently physically
inactive and many ILD subtypes are characterized by risk factors for myopathy; however, the …
inactive and many ILD subtypes are characterized by risk factors for myopathy; however, the …
Comorbidities of IPF: How do they impact on prognosis
SE Torrisi, A Vancheri, M Pavone, G Sambataro… - Pulmonary …, 2018 - Elsevier
Abstract Idiopathic Pulmonary Fibrosis (IPF) is a severe parenchymal lung disease
characterized by an intense deposition of collagen in the interstitial spaces. The introduction …
characterized by an intense deposition of collagen in the interstitial spaces. The introduction …